ARS Pharmaceuticals, Inc.
SPRY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SPRY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SPRY
ARS Pharmaceuticals, Inc. (SPRY) is a commercial-stage biopharmaceutical company focused on developing and commercializing neffy, an intranasal epinephrine product for the treatment of allergic reactions including anaphylaxis.
Key risk: Commercial adoption risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$585.7M
Cash Runway
7.7 moLead Asset
intranasal epinephrine technology product candidates (Phase 2)
Next Catalyst
Phase3_Topline · Dec 29, 2028Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 13 clinical trials · 1 catalyst for ARS Pharmaceuticals, Inc..
Similar companies
ARS Pharmaceuticals, Inc. (SPRY) is a commercial-stage biopharmaceutical company focused on developing and commercializing neffy, an intranasal epinephrine product for the treatment of allergic reactions including anaphylaxis.
- As of June 30, 2026, ARS Pharmaceuticals had cash, cash equivalents, and short-term investments of $143.8 million [sec_mda · as of 2026-08-13].
- The company's primary product is neffy (intranasal epinephrine), approved by the FDA for the treatment of allergic reactions including anaphylaxis [sec_mda · as of 2026-08-13].
- ARS Pharmaceuticals has incurred net losses in most years and reported a net loss of -$62.3M for the six months ended June 30, 2026 [sec_mda · as of 2026-08-13].
- The company has entered into multiple collaboration and licensing agreements, including with ALK, Pediatrix Therapeutics, Aegis Therapeutics, Alfresa Pharma, and Recordati [sec_mda · as of 2026-08-13].
- Management believes existing cash, product sales, and collaboration proceeds will fund operations through at least the next three years [sec_mda · as of 2026-03-09].
What works
- neffy is a novel intranasal epinephrine product that addresses a large market for anaphylaxis treatment, potentially offering a needle-free alternative to auto-injectors [sec_mda · as of 2026-08-13].
- The company has established multiple commercial partnerships (e.g., ALK, Pediatrix, Alfresa) to expand neffy's global reach and generate milestone and royalty revenue [sec_mda · as of 2026-08-13].
- With $143.8 million in cash and short-term investments as of June 30, 2026, the company has a solid financial runway to support commercial launch and ongoing R&D [sec_mda · as of 2026-08-13].
What to weigh
- ARS Pharmaceuticals has a history of net losses and may continue to incur losses as it scales commercial operations and invests in clinical trials [sec_mda · as of 2026-08-13].
- The company's future success is heavily dependent on the commercial adoption of neffy, which faces competition from established epinephrine auto-injectors [sec_mda · as of 2026-08-13].
- Cash burn from ongoing R&D and commercialization could deplete resources sooner than expected if revenue from neffy does not materialize as projected [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash, cash equivalents, and short-term investments of $143.8 million.”
SEC MD&A · August 13, 2026
Net losses incurred historically
“We have incurred net losses in most years”
SEC MD&A · August 13, 2026
Sufficient cash runway for at least three years
“we believe that our existing cash, cash equivalents, short-term investments, and revenues from product sales and cash proceeds from collaboration and out-licensing agreements will be sufficient to meet our anticipated cash requirements through at least the next three years.”
SEC MD&A · March 9, 2026
Risks & what to watch (3)›
Key risks
- Commercial adoption risk — neffy's market success depends on physician and patient adoption versus established auto-injectors [sec_mda · as of 2026-08-13].
- Cash burn and funding needs — Ongoing R&D and commercialization costs may deplete cash faster than expected if revenue falls short [sec_mda · as of 2026-08-13].
- Regulatory and clinical delays — Expansion to additional indications requires costly clinical trials with uncertain timelines [sec_mda · as of 2026-08-13].
What to watch
- Commercial launch performance of neffy and revenue growth trajectory [sec_mda · as of 2026-08-13]
- Progress of clinical trials for additional indications of intranasal epinephrine [sec_mda · as of 2026-08-13]
- Milestone and royalty payments from collaboration partners (ALK, Pediatrix, etc.) [sec_mda · as of 2026-08-13]
- Cash burn rate and any need for additional financing [sec_mda · as of 2026-08-13]
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ARS Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARS Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
7.7 months
D/E 18.94 · 0% dilution
Lead: Phase 2
1 candidate
1 upcoming, next in ~852d
0 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
200
Total value held
$626.4M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 10,860,977 | $87.2M |
| orbimed advisors llc | 8,288,510 | $66.6M |
| deerfield management company, l.p. | 7,503,812 | $60.3M |
| millennium management llc | 5,982,919 | $48.0M |
| vanguard capital management llc | 5,085,008 | $40.8M |
| blackrock, inc. | 5,012,254 | $40.2M |
| state street corp | 3,644,966 | $29.3M |
| franklin resources inc | 3,278,549 | $26.3M |
| tyro capital management llc | 2,968,599 | $23.8M |
| ubs group ag | 2,260,325 | $18.2M |
Showing top 10 of 200 institutional holders of ARS Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 41.5%
- Days to cover
- 15.7
- Shares short
- 25,341,296
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SPRY short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. (SPRY) is a commercial-stage biopharmaceutical company focused on developing and commercializing neffy, an intranasal epinephrine product for the treatment of allergic reactions including anaphylaxis.
What is ARS Pharmaceuticals, Inc.'s lead drug candidate?
ARS Pharmaceuticals, Inc.'s most advanced tracked candidate is intranasal epinephrine technology product candidates (Phase 2) for Urticaria Chronic.
What is ARS Pharmaceuticals, Inc.'s next catalyst?
ARS Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With" — expected December 29, 2028.
Who is the CEO of ARS Pharmaceuticals, Inc.?
Mr. Donn Casale is the chief executive officer of ARS Pharmaceuticals, Inc. (SPRY).
Where is ARS Pharmaceuticals, Inc. headquartered?
ARS Pharmaceuticals, Inc. (SPRY) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.